Category: Neurology
-
Modulight secures $12 million for neurological disorders treatment
The company closed a seed funding round to advance its novel optogenetic platform for treating neurological disorders like chronic pain and epilepsy.
-
Teva unveils real-world findings for tardive dyskinesia treatment
Teva’s latest study finds Austedo and Austedo XR reduce involuntary movements and improve quality of life in tardive dyskinesia patients.
-
FDA approves first robotic microsurgical study in Alzheimer’s
MMI earns FDA IDE approval for a groundbreaking robotic microsurgery trial targeting Alzheimer’s disease.
-
ten23 health and Neumirna partner to advance RNA therapy for epilepsy
The collaboration seeks to advance NMT.001, an RNA-based therapy targeting microRNAs involved in drug-resistant epilepsy.
-
FDA expands Teva’s Uzedy approval to include bipolar I disorder
Teva’s long-acting subcutaneous formulation of Johnson and Johnson’s (J&J) Risperdal is already approved for schizophrenia.
-
RadioMedix and Vect-Horus launch exploratory cancer radiopharmaceutical study
The first patient has been dosed in an exploratory Investigational New Drug (IND) study targeting glioblastoma multiforme and pancreatic cancer.
-
ARC and Revealense partner on at-home AI diagnostics
The collaboration will initially focus on autism spectrum disorder and ADHD, with market launch expected in 2026.
-
Labcorp launches first FDA-cleared blood test for Alzheimer’s
Following the news, Labcorp’s stock rose by almost 2% at market close on 19 August, and is currently trading at $277.83, up 2.7%.
-
Teva’s stock rises with Ajovy’s expanded FDA approval
Ajovy is now approved by the US FDA as a preventive treatment for episodic migraine in children aged 6–17.
-
Porosome’s bold bet on Alzheimer’s: Nanomachines, AI, and a cure?
Porosome Therapeutics reveals organoid studies, Tau targeting, and AI-designed peptides, marking new directions in Alzheimer’s treatment.
-
Linus Health brings AI to the forefront of Alzheimer’s detection
Boston-based startup unveils AI-powered tools at AAIC 2025 to aid early Alzheimer’s detection and trial recruitment.
-
FDA Adcom to Weigh Conflicting Data on Rexulti-Zoloft combo for PTSD
FDA’s upcoming advisory panel will assess whether one positive and one negative Phase III trial, plus exploratory data, support approval.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.